Acoustic Tumor Therapy (HIFU and beyond)
Note: This page is educational and reflects the state of the literature in 2025. It does not replace medical advice.
TL;DR
Acoustic cancer therapy uses focused ultrasound (FUS / HIFU) — externally generated mechanical waves — to do one of three things at a tumor: heat it (thermal ablation), mechanically disrupt it (histotripsy), or transiently open the blood–brain barrier (BBB) and other vascular barriers so that drugs can reach targets they otherwise couldn't.Approved indications today include uterine fibroids, bone metastasis pain, prostate cancer, essential tremor, and a growing set of investigational oncology uses. The technology is non-ionizing, non-invasive, and image-guided — but treatment-effect heterogeneity, monitoring, and access remain limiting. Sources: [1]
1. Three modes of action
| Mode | Effect | Where |
|---|---|---|
| Thermal ablation | Raise tissue to 55–80 °C in seconds; coagulative necrosis | Prostate, fibroids, bone metastases, liver, pancreas (research) |
| Histotripsy | Pulsed ultrasound creates cavitation bubbles that mechanically lyse tissue | Liver tumors (FDA cleared, Histosonics 2023), pancreas, kidney research |
| Sonoporation / drug delivery | Microbubbles + ultrasound transiently permeabilize cell membranes and BBB | Glioma (BBB opening), breast, pancreas |
| Sonodynamic therapy (SDT) | Sound + sonosensitizer drug → ROS → cell death (analog of PDT for deep tumors) | Glioma research, deep solid tumors |
The first two destroy tissue directly; the second two enable other therapies. Sources: [1]
2. Approved and clinically established uses
- Uterine fibroids — MR-guided HIFU is approved in many jurisdictions for symptomatic fibroids.
- Prostate cancer — focal HIFU (e.g., Sonablate, Ablatherm) for low/intermediate-risk localized disease; not curative for high-risk but avoids surgery and full-gland radiation.
- Bone metastasis pain — MR-guided HIFU is FDA-cleared for palliation of bone-metastasis pain refractory to radiation.
- Histotripsy of liver tumors — FDA cleared in 2023 for non-invasive destruction of liver tumors (HCC, metastases) via mechanical cavitation only, no thermal injury.
- Essential tremor (non-cancer) — MR-guided HIFU thalamotomy, included here because it shaped the device ecosystem.
3. Investigational frontiers
- BBB opening for brain tumors. Microbubbles + low-intensity focused ultrasound transiently open the BBB, letting chemotherapy (e.g., carboplatin), antibodies, or even gene therapy reach gliomas. Multiple Phase I/II trials in glioblastoma and pediatric DIPG. Sources: [1]
- Pancreatic cancer. Both thermal HIFU and sonoporation-enhanced gemcitabine/nab-paclitaxel under study to overcome dense stromal barrier.
- Sonodynamic therapy (SDT). Sound-activated sensitizers offer PDT-like effects but at greater tissue depth; early glioma trials.
- Immune-mediated effects. Like other ablative modalities, HIFU releases tumor antigens and DAMPs; trials combining HIFU with checkpoint inhibitors aim to provoke an "abscopal" response, mirroring the cryoablation rationale (Cryoablation + immunotherapy).
4. Image guidance and monitoring
Real-time imaging is integral:
- MR-guided HIFU (MRgFUS) — temperature mapping with proton-resonance frequency shift; precise targeting at the cost of magnet access.
- Ultrasound-guided HIFU — cheaper, real-time, no magnet; harder to monitor temperature directly.
- Histotripsy monitoring — bubble cloud visualization on US.
5. Strengths and limits
Strengths
- Non-ionizing (no cumulative radiation dose).
- Non-invasive (no incision, no needle for many indications).
- Repeatable.
- Combinable with systemic therapy.
Limits
- Acoustic windows — bone (especially skull) blocks ultrasound; cranial HIFU requires special transducer arrays.
- Targeting accuracy in moving organs (lung, liver with respiration).
- Treatment time for large lesions.
- Cost and access — capital cost of MR-coupled devices.
- Modest randomized evidence in some indications (depends on which).
6. What technologists can build
- Treatment planning — Monte Carlo or wave-equation simulation of acoustic field, integrated with imaging.
- Real-time temperature / cavitation analytics — fuse MR thermometry, US, and treatment logs.
- Robotic transducer positioning — image-guided alignment, especially for histotripsy.
- Microbubble pharmacology models — for sonoporation drug delivery dosing.
- Outcome registries to capture real-world response across modalities.
7. Brazilian context
- HIFU for uterine fibroids and prostate is available in selected private centers; SUS coverage is limited.
- Academic groups in physics and biomedical engineering (USP, UNICAMP, UFMG) work on transducer design, treatment planning, and sonoporation.
- ANVISA registration of HIFU devices follows the SaMD/medical-device frameworks.
See also
- Cryoablation + immunotherapy
- Photodynamic therapy
- Magnetic hyperthermia
- Emerging therapies
- Medical physics
References
- Bachu VS, Kedda J, Suk I, Green JJ, Tyler B. High-Intensity Focused Ultrasound: A Review of Mechanisms and Clinical Applications. Ann Biomed Eng 2021;49:1975-1991. PMID 34374945. https://doi.org/10.1007/s10439-021-02833-9
- U.S. National Cancer Institute. https://www.cancer.gov/about-cancer/understanding/what-is-cancer
- American Cancer Society. https://www.cancer.org/cancer.html
- Cleveland Clinic. Cancer (overview). https://my.clevelandclinic.org/health/diseases/12194-cancer
- A.C. Camargo Cancer Center. https://accamargo.org.br
- Fundação do Câncer (Brasil). https://www.cancer.org.br/
- Ministério da Saúde / BVS. ABC do câncer. https://bvsms.saude.gov.br/bvs/publicacoes/abc_do_cancer.pdf
- ANVISA — Agência Nacional de Vigilância Sanitária. https://www.gov.br/anvisa/pt-br